Active Biotech Announces New Data from Exploratory Analysis of the Phase 2 LEGATO-HD Study of Laquinimod in Huntington's Disease to be Presented at the International Congress of Parkinson's Disease and Movement Disorders
September 23, 2019 at 02:30 am EDT
Active Biotech AB (publ) announced that new data from exploratory analysis of the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the International congress of Parkinson's disease and Movement disorders in Nice, France, September 22-26, 2019. The data will be presented in three posters.